Abeta42 gene vaccine prevents Abeta42 deposition in brain of double transgenic mice.
about
Immunization with the SDPM1 peptide lowers amyloid plaque burden and improves cognitive function in the APPswePSEN1(A246E) transgenic mouse model of Alzheimer's disease.Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer NetworkThe MultiTEP platform-based Alzheimer's disease epitope vaccine activates a broad repertoire of T helper cells in nonhuman primates.Evaluation of a DNA Aβ42 vaccine in adult rhesus monkeys (Macaca mulatta): antibody kinetics and immune profile after intradermal immunization with full-length DNA Aβ42 trimer.DNA Aβ42 vaccination as possible alternative immunotherapy for Alzheimer disease.A peptide prime-DNA boost immunization protocol provides significant benefits as a new generation Aβ42 DNA vaccine for Alzheimer disease.DNA beta-amyloid(1-42) trimer immunization for Alzheimer disease in a wild-type mouse model.Analysis of three plasmid systems for use in DNA A beta 42 immunization as therapy for Alzheimer's disease.Co-stimulation with TNF receptor superfamily 4/25 antibodies enhances in-vivo expansion of CD4+CD25+Foxp3+ T cells (Tregs) in a mouse study for active DNA Aβ42 immunotherapyAmyloid-β immunization enhances neurogenesis and cognitive ability in neonatal mice.Yeast expressed foldable quadrivalent Aβ15 elicited strong immune response against Aβ without Aβ-specific T cell response in wild C57BL/6 mice.Advances in the development of vaccines for Alzheimer's disease.Epitope-based DNA vaccine for Alzheimer's disease: translational study in macaques.Neutralization of granulocyte macrophage colony-stimulating factor decreases amyloid beta 1-42 and suppresses microglial activity in a transgenic mouse model of Alzheimer's disease.Immunotherapeutic efficiency of a tetravalent Aβ1-15 vaccine in APP/PS1 transgenic mice as mouse model for Alzheimer's diseaseEvaluation of a DNA Aβ42 Vaccine in Aged NZW Rabbits: Antibody Kinetics and Immune Profile after Intradermal Immunization with Full-Length DNA Aβ42 TrimerActive DNA Aβ42 vaccination as immunotherapy for Alzheimer disease.Active immunotherapy options for Alzheimer's disease.Immunogenicity of DNA- and recombinant protein-based Alzheimer disease epitope vaccines.Anti-amyloid beta to tau - based immunization: Developments in immunotherapy for Alzheimer disease.A noninflammatory immune response in aged DNA Aβ42-immunized mice supports its safety for possible use as immunotherapy in AD patients.The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model.DNA immunization against amyloid beta 42 has high potential as safe therapy for Alzheimer's disease as it diminishes antigen-specific Th1 and Th17 cell proliferationAstrocytes with previous chronic exposure to amyloid β-peptide fragment 1-40 suppress excitatory synaptic transmission.In vivo electroporation of a new gene vaccine encoding ten repeats of Aβ3-10 prevents brain Aβ deposition and delays cognitive impairment in young Tg-APPswe/PSEN1dE9 mice.Perspectives in molecular imaging using staging biomarkers and immunotherapies in Alzheimer's disease.Application of immunosignatures to the assessment of Alzheimer's disease.
P2860
Q24599108-DCF5014B-F681-4AE9-B5BF-98674C8C9286Q28714253-71AD1507-61AC-490B-A282-D5B1E0291DBAQ33560798-878523AA-66EC-4696-9B7F-9008FE2DE042Q33604583-D14EF8DB-3B11-4B9B-B099-47EE25A85BA8Q33829380-F3998601-6D57-4912-9E52-E1B5AA476533Q33855619-9D5B253E-7B3C-46F0-A296-C050009910B9Q33957114-ED0D9990-3246-47FB-8458-DE5FC272E53FQ34080692-6EA14B7E-BE32-4A83-A462-7001DF923148Q35000579-72E7570D-86FD-4009-84A1-E8BB1E6AD1E1Q35792042-1D84CFE2-3B4C-4542-99EF-07BE6AF7736AQ36552898-5FA159D8-D43C-4BC4-832C-D76D5AF3A8CBQ36965988-36FB4736-2B50-4031-8DF6-2749EEBECB2FQ37303082-92118885-CAEA-4EB4-B917-4CE10B4D4A9CQ37357640-6C262B7D-B36E-4A12-97A9-912091CC4D96Q37530061-840DCEF3-A91B-4ECE-8057-F6A9B49B00DBQ37693367-32EC938F-B8D3-4492-883D-BCBAD7E85D3AQ38112430-74B098C3-69D1-4017-988E-FCE448986E90Q38183140-4E338A72-FAF1-4721-A50E-8831753D97F1Q38187861-5A22AFE4-6135-4973-ACF3-395BDEA54497Q38219981-093AE983-EB0D-41E3-AD69-093397F4B814Q39373266-C4CB5ABC-5B8D-4F2C-AB96-122D0CC8326AQ39432793-2CCA1957-0803-47BA-B179-48610A70BB4DQ41783861-190BDB58-8B9C-45EB-B830-21463FA53521Q47596419-73B33045-4AA7-43A1-BE55-996CB3E24206Q48603497-6CFE26B2-91F2-4FB1-99E2-96632A20C210Q51481172-1679A250-F265-4643-9A18-BE3A0C087B46Q53427707-2197F31A-FE33-4AD9-8130-6A26023418F7
P2860
Abeta42 gene vaccine prevents Abeta42 deposition in brain of double transgenic mice.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Abeta42 gene vaccine prevents Abeta42 deposition in brain of double transgenic mice.
@en
type
label
Abeta42 gene vaccine prevents Abeta42 deposition in brain of double transgenic mice.
@en
prefLabel
Abeta42 gene vaccine prevents Abeta42 deposition in brain of double transgenic mice.
@en
P2093
P2860
P1476
Abeta42 gene vaccine prevents Abeta42 deposition in brain of double transgenic mice
@en
P2093
Roger N Rosenberg
Stephen Albert Johnston
P2860
P304
P356
10.1016/J.JNS.2007.05.012
P577
2007-06-15T00:00:00Z